Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ironwood Pharmaceuticals

0.8885
+0.00981.12%
Post-market: 0.8800-0.0085-0.96%19:58 EDT
Volume:2.93M
Turnover:2.59M
Market Cap:143.77M
PE:160.64
High:0.9337
Open:0.9337
Low:0.8200
Close:0.8787
Loading ...

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Business Wire
·
14 Nov 2024

Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down

Zacks
·
09 Nov 2024

Stock Track | Ironwood Pharmaceuticals Surges 5% on Robust LINZESS Growth and Pipeline Progress

Stock Track
·
08 Nov 2024

Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...

GuruFocus.com
·
08 Nov 2024

Ironwood Pharmaceuticals Reports Q3 2024 Performance

TIPRANKS
·
08 Nov 2024

Ironwood Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
08 Nov 2024

Stock Track | Ironwood Pharmaceuticals Reports Disappointing Q3 Results, Stock Plunges

Stock Track
·
07 Nov 2024

Stock Track | Ironwood Pharmaceuticals Misses Q3 Earnings Estimate, Outlook Maintained

Stock Track
·
07 Nov 2024

Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates

Zacks
·
07 Nov 2024

Ironwood: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

Ironwood Pharmaceuticals Continues To Expect 2024 Total Revenue Of $350M-$375M Vs. Consensus Of $357.181M

Benzinga
·
07 Nov 2024

Ironwood Pharmaceuticals Q3 2024 Adj. EPS $0.02 Misses $0.08 Estimate, Sales $91.592M Beat $91.248M Estimate

Benzinga
·
07 Nov 2024

BRIEF-Ironwood Pharmaceuticals Q3 Revenue USD 91.592 Million Vs. IBES Estimate USD 91.2 Million

Reuters
·
07 Nov 2024

Ironwood Pharmaceuticals Inc: Maintains Full Year 2024 Financial Guidance

THOMSON REUTERS
·
07 Nov 2024

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Business Wire
·
07 Nov 2024

Ironwood Says Apraglutide Shows 'Consistent Treatment Effect' in Short Bowel Syndrome; Shares Rise

MT Newswires Live
·
28 Oct 2024

Ironwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study

Dow Jones
·
28 Oct 2024

BRIEF-Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics And Disease Characteristics In Adults With Short Bowel Syndrome With Intestinal Failure (Sbs-If), According To New Stars Phase Iii Data From Ironwood At Acg 2024

Reuters
·
28 Oct 2024

Ironwood to present new findings from STARS trial at ACG

TIPRANKS
·
28 Oct 2024

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults With Short Bowel Syndrome With Intestinal Failure (SBS-IF), According to New Stars Phase Iii Data From Ironwood at Acg 2024

THOMSON REUTERS
·
28 Oct 2024